Contents

Cancer Research
August 1, 2013 • Volume 73 • Number 15

BREAKING ADVANCES

4595 Highlights from Recent Cancer Literature

OBITUARY

4597 Emil Frei III, MD: In Memoriam (1924–2013)

REVIEWS

4599 A Road Map to Comprehensive Androgen Receptor Axis Targeting for Castration-Resistant Prostate Cancer
Nicholas Mitsiades

4606 Myeloid-Derived Suppressor Cells as Osteoclast Progenitors: A Novel Target for Controlling Osteolytic Bone Metastasis
Anandi Sawant and Selvarangan Ponnazhagan

PERSPECTIVE

4611 Cancer Research Advocacy: Past, Present, and Future
Jane Perlmutter, Shannon K. Bell, and Gwen Darien

INTEGRATED SYSTEMS AND TECHNOLOGIES

4616 Quantitative In Vivo Characterization of Intracellular and Extracellular pH Profiles in Heterogeneous Tumors: A Novel Method Enabling Multiparametric pH Analysis
Norbert W. Lutz, Yann Le Fur, Johanna Chiche, Jacques Pouyssegur, and Patrick J. Cozzone

MICROENVIRONMENT AND IMMUNOLOGY

4629 Tumor Promotion by Intratumoral Plasmacytoid Dendritic Cells Is Reversed by TLR7 Ligand Treatment
Isabelle Le Mercier, Dominique Poujol, Amélie Sanlaville, Vanja Sisirak, Michael Gobert, Isabelle Durand, Bertrand Dubois, Isabelle Treilleux, Jacqueline Marvel, Jaromir Vlach, Jean-Yves Blay, Nathalie Bendriss-Vermare, Christophe Caux, Isabelle Puiseux, and Nadège Goutagny

Précis: This study suggests a new use in breast cancer treatment for synthetic ligands of TLR7 like imiquimod that are used widely as immunomodulators in clinic.

4641 Vaccine-Instructed Intratumoral IFN-γ Enables Regression of Autochthonous Mouse Prostate Cancer in Allogeneic T-Cell Transplantation
Rodrigo Hess Michelini, Teresa Manzo, Tabea Sturmheit, Veronica Basso, Martina Rocchi, Massimo Freschi, Joanna Listopad, Thomas Blankenstein, Matteo Bollone, and Anna Mondino

Précis: Findings argue that cancer vaccines that improve antitumor T-cell responses can cooperate strongly with allogeneic bone marrow transplants to convert them into effective treatments for solid tumors.

4653 IL-18–Primed Helper NK Cells Collaborate with Dendritic Cells to Promote Recruitment of Effector CD8+ T Cells to the Tumor Microenvironment
Jeffrey L. Wong, Erik Berk, Robert P. Edwards, and Pawel Kalinski

Précis: Results advance understanding of how NK cells can provide an initial stimulus to orchestrate the attraction of dendritic cells and additional effector cells into the cancer microenvironment.

4663 Potent Immunomodulatory Effects of the Trifunctional Antibody Catumaxomab
Diane Goezié, Caroline Flamant, Sylvie Busakiewicz, Vichnou Potier-Colame, Oliver Kepp, Isabelle Martins, Julien Pesquet, Alexander Eggermont, Dominique Elias, Nathalie Chaput, and Laurence Zitvogel

Précis: This study reports a comprehensive dissection of the immunomodulatory effects of a bispecific mAb specific for a widely expressed tumor cell adhesion molecule and the T-cell molecule CD3, which is one of the first bispecific mAbs to be explored in clinic.
Intravital FLIM-FRET Imaging Reveals Dasatinib-Induced Spatial Control of Src in Pancreatic Cancer


Precise: Defining the spatial and temporal factors that limit drug targeting in live tumors could help optimize the preclinical development of new therapeutic agents.

PLZF Confers Effector Functions to Donor T' Cells That Preserve Graft-versus-Tumor Effects while Attenuating GVHD

Arnab Ghosh, Amanda M. Holland, Yildirim Dogan, Nurul L. Yim, Utartan K. Rao, Lauren F. Young, Mallory L. West, Natalie V. Singer, Hae Lee, Il-Kang Na, Jennifer J. Tsai, Robert R. Jeng, Olaf Penack, Alan M. Hanash, Cecilize Lezcano, George F. Murphy, Chen Liu, Michel Sadelain, Martin G. Sauer, Derek San't Angelo, and Marcel R.M. van den Brink

Precise: This study describes a strategy to improve the qualities of adoptive cell therapies that use alloreactive T cells for immunotherapy treatment of cancer, focusing particularly on the reduction of undesirable graft-versus-host side effects.

Progesterone Receptor Signaling in the Microenvironment of Endometrial Cancer Influences Its Response to Hormonal Therapy

Deanna M. Janzen, Miguel A. Rosales, Daniel Y. Paik, Daniel S. Lee, Daniel A. Smith, Owen N. Witte, M. Luisa Irueula-Arispe, and Sanaz Memarzadeh

Precise: Striking findings show that the efficacy of hormonal therapy in endometrial cancer is not related to effects on cancer cells, but rather to effects on stromal cells where the progesterone receptor is necessary and sufficient to mediate antitumor effects in the microenvironment.

Proteomic and Lipidomic Signatures of Lipid Metabolism in NASH-Associated Hepatocellular Carcinoma

Kyle Muir, Antoniaziu Hazim, Ying He, Marion Peyressatre, Do-Young Kim, Xiaoling Song, and Laura Beretta

Precise: This study reveals a role for lipid-modifying enzymes in liver cancer, identifying in particular a specific type of long-chain polyunsaturated fatty acid participating in nonalcoholic steatohepatitis and liver cancer risk.

Posttranscriptional Regulation of PER1 Underlies the Oncogenic Function of IRE1α


Precise: Circadian rhythms that may affect chemotherapeutic efficacy are linked here for the first time to the unfolded protein response, a signaling pathway widely activated in cancer that plays an important role in tumor aggressiveness.

Peroxiredoxin-2 Represses Melanoma Metastasis by Increasing E-Cadherin/β-Catenin Complexes in Adherens Junctions

Doo Jae Lee, Dong Hoon Kang, Mina Choi, Yang Ji Choi, Joo Young Lee, Joo Hyun Park, Yoon Jung Park, Kyung Wha Lee, and Sang Won Kang

Precise: In discovering a specific antioxidant enzyme that can repress melanoma metastasis, this study also suggests a tractable new direction to treat this deadly disease.

TR3 Modulates Platinum Resistance in Ovarian Cancer

Andrew J. Wilson, Annie Y. Liu, Joseph Roland, Oluwafunmilayo A. Adebayo, Sarah A. Fletcher, James C. Slaughter, Jeanette Saskowski, Marta A. Crispens, Howard W. Jones III, Samuel James, Oluwole Fadare, and Dineo Khabele

Precise: There remains great interest in determining general strategies to overcome resistance to platinum compounds that are used very widely to treat cancer, including ovarian cancer.
**Prevention and Epidemiology**

4770

**Genetic Ablation of the Fatty Acid-Binding Protein FABP5 Suppresses HER2-Induced Mammary Tumorigenesis**

Liraz Levi, Glenn Lobo, Mary Kathryn Doud, Johannes von Lintig, Darcie Seachrist, Gregory P. Tochtrip, and Noa Noy

_Precise:_ A protein that delivers fatty acids to the transcription factor PPARG is critical for mammary tumor development, rationalizing the development of FABP5 inhibitors to prevent or treat breast cancer.

4781

**PanIN-Specific Regulation of Wnt Pathway-Based Serum microRNA PanIN-Specific Regulation of Wnt**

Angela Criscimanna, Li-Juan Duan, Julie A. Rhodes, Volker Fendrich, Emily Wickline, Douglas J. Hartman, Satdarshan P.S. Monga, Michael T. Lotze, George K. Gittes, Guo-Hua Fong, and Farzad Esni

_Precise:_ This study identifies root signaling connections between hypoxia control and the Wnt and Smad4 pathways in early development of pancreatic cancer.

4791

**Enhanced Radiation Sensitivity in HPV-Positive Head and Neck Cancer**


_Precise:_ Activation of residual p53 in HPV+ head and neck cancers may explain why this type of disease has a relatively better outcome in patients.

**Therapeutics, Targets, and Chemical Biology**

4820

**Novel Recombinant Human B7-H4 Antibodies Overcome Tumoral Immune Escape to Potentiate T-Cell Antitumor Responses**

Denarda Dangaj, Evripidis Lanitis, Aizhi Zhao, Shree Joshi, Yi Cheng, Raphael Sandaltzopoulos, Hyun-Jeong Ra, Gwern Danet-Desnoyers, Daniel J. Powell, Jr, and Nathalie Scholler

_Precise:_ Blockade of inhibitory T-cell receptor signals in the same general family as the CTLA-4 molecule targeted by ipilimumab (Yervoy) may offer a paradigm for simultaneous targeting of not only tumor cells, but also tumor-associated macrophages that drive immune escape.

4830

**Transcription Poisoning by Topoisomerase I Is Controlled by Gene Length, Splice Sites, and miR-142-3p**

Stéphanie Solier, Michael C. Ryan, Scott E. Martin, Sudhir Varma, Kurt W. Kohn, Hongfang Liu, Barry R. Zeeberg, and Yves Pommier

_Precise:_ Camptothecins used in cancer therapy may act to a major extent by targeting a p53-dependent microRNA.

4840

**C-RAF Mutations Confer Resistance to RAF Inhibitors**

Rajee Antony, Caroline M. Emery, Allison M. Sawyer, and Levi A. Garraway

_Precise:_ These findings may provide a rationale for the future development of allosteric or pan-RAF inhibitors that disrupt the RAF dimerization interface.

4850

**Pivotal Role of the Lipid Raft SK3–Orai1 Complex in Human Cancer Migration and Bone Metastases**


_Precise:_ This study links a therapeutically targetable potassium channel to bone metastasis, a common feature of advanced breast and prostate cancers that is generally untreatable.

4860

**Docetaxel Conjugate Nanoparticles That Target α-Smooth Muscle Actin–Expressing Stromal Cells Suppress Breast Cancer Metastasis**

Mami Murakami, Mark J. Ernsting, Elijus Undzys, Nathan Holwell, Warren D. Foltz, and Shyh-Dar Li

_Precise:_ A novel cytotoxic nanoparticle that specifically degrades stromal elements in the tumor microenvironment exhibits potent antitumor activity.
4872  **LIN28 Expression in Malignant Germ Cell Tumors Downregulates let-7 and Increases Oncogene Levels**

**Précis:** This study defines a common oncogenic pathway in malignant germ cell tumors (GCT) and offers preclinical initial proof of concept for its targeting potential in this setting.

4885  **A Renewable Tissue Resource of Phenotypically Stable, Biologically and Ethnically Diverse, Patient-Derived Human Breast Cancer Xenograft Models**
Xiaomei Zhang, Sofie Claerhout, Aleix Pratt, Lacey E. Dobrolecki, Ivana Petrovic, Qing Lai, Melissa D. Landis, Lisa Wiechmann, Lisa Wiechmann, Rachel Schiff, Mario Giuliano, Helen Wong, Suzanne W. Fuqua, Alejandro Contreras, Carolina Gutierrez, Jian Huang, Sufeng Mao, Anne C. Pavlick, Anna Tsimelzon, Susan G. Hilsenbeck, Edward S. Chen, Pavel Zuloaga, Chad A. Shaw, Michael T. Lewis

**Précis:** This well-characterized collection of human breast cancer xenografts will serve as a foundation for conduct of "animal clinical trials" to evaluate experimental therapeutics, as well as a resource for mechanistic studies of treatment resistance and metastasis.

4898  **eIF4B Phosphorylation by Pim Kinases Plays a Critical Role in Cellular Transformation by Abi Oncogenes**
Jianling Yang, Jun Wang, Ke Chen, Guijie Gao, Ruijiao Xi, Paul B. Rothman, Douglas Whitten, Lianfeng Zhang, Shile Huang, and Ji-Long Chen

**Précis:** Results identify the translation initiation factor eIF-4B as a critical substrate of Pim kinases, which mediate the activity of Abi oncogenes, suggesting this factor as a candidate therapeutic target in Abi-induced cancers.

4909  **Canonical Wnt Signaling Is Required for Pancreatic Carcinogenesis**
Yaqing Zhang, John P. Morris IV, Wei Yan, Heather K. Schofield, Austin Gurney, Diane M. Simeone, Sarah E. Millar, Timothy Hoey, Matthias Hebrok, and Marina Pasca di Magliano

**Précis:** This study establishes a causal role for WNT pathway signaling in the development and progression of Kras-initiated pancreatic cancers, with therapeutic implications for the use of WNT pathway antagonists in this deadly disease.

4923  **Aptamer Identification of Brain Tumor–Initiating Cells**
Youngmi Kim, Qiulian Wu, Petra Hamerlik, Masahiro Hitomi, Andrew E. Sloan, Gene H. Barnett, Robert J. Weil, Patrick Leahey, Anita B. Hjelmeland, and Jeremy N. Rich

**Précis:** This work illustrates a general method to prospectively isolate tumor-initiating cells, the imaging and targeting of which may be important for improving therapeutic outcomes in individual patients.

4937  **Loss of p120-Catenin Induces Metastatic Progression of Breast Cancer by Inducing Anoikis Resistance and Augmenting Growth Factor Receptor Signaling**

**Précis:** Based on conditional mouse models of metastatic breast cancer that are immunocompetent and clinically relevant, the current study provides an alternate rationale for therapeutic intervention of p120-catenin negative invasive breast cancer.

4950  **TRAF6 Upregulates Expression of HIF-1α and Promotes Tumor Angiogenesis**
Heng Sun, Xue-Bing Li, Ya Meng, Li Fan, Min Li, and Jing Fang

**Précis:** A factor well studied in the TNF response and implicated in innate and adaptive immune control is established in this study to control tumor angiogenesis.

**RETRACTION**

4960  **Retraction: Sp100 as a Potent Tumor Suppressor: Accelerated Senescence and Rapid Malignant Transformation of Human Fibroblasts through Modulation of an Embryonic Stem Cell Program**

**CORRECTION**

4962  **Correction: IKK4α/ARF Inactivation with Activation of the NF-κB/IL-6 Pathway Is Sufficient to Drive the Development and Growth of Angiosarcoma**
ABOUT THE COVER

Schematic representation of the IRE1α-dependent activation loop that controls tumor cell adaptation. Tumor cell is presented in light gray, stromal cells in dark gray. Proteins are represented by circles, with upregulation in green and downregulation in red. Connections following stress-mediated activation of IRE1α are presented in green for activation and red for inhibition. For details, see article by Pluquet and colleagues on page 4732.
Cancer Research

73 (15)


Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/73/15

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.